Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

Jason Luke, MD
Published: Friday, Oct 27, 2017



Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

A combination that is of a lot of interest is a PD-1 antibody and an oncolytic virus, states Luke. There are drugs that are approved for each as a monotherapy, but the combination of pembrolizumab and T-VEC has the potential to be promising.

T-VEC is a modified virus that is injected into melanoma tumors that are on the skin.  
SELECTED
LANGUAGE


Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

A combination that is of a lot of interest is a PD-1 antibody and an oncolytic virus, states Luke. There are drugs that are approved for each as a monotherapy, but the combination of pembrolizumab and T-VEC has the potential to be promising.

T-VEC is a modified virus that is injected into melanoma tumors that are on the skin.  

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x